Speedel, a Swiss drugmaker who have been testing a type of experimental diabetes drug, have had to halt their trial following alarmingly high levels of dangerous side effects that threatened the health of patients.
An independent panel of experts advised Speedel to halt their trial of Avosenta, following overwhelming fluid retention amongst patients. The treatment, which held great potential for diabetes sufferers, may still have a role to play in the prevention of other illnesses.
In response to the news, the Swiss drugmaker lost a quarter of their value as shares slumped. Alice Huxley, the Chief Executive Officer, said: “We’re confident the drug still has potential.” The news is typical of drugmaker efforts to advance new drugs. Huxley concluded: “We’re pushing the boundaries of medicine further and further. If you’re at the forefront of innovation then you’re the first to take the risk and learn the lesson. But you can turn a bitter pill into an advantage.”

Get our free newsletters

Stay up to date with the latest news, research and breakthroughs.

You May Also Like

Twice daily dairy intakes could reduce type 2 diabetes risk

Eating cheese, yoghurt or eggs twice a day could help lower the…

Type 2 diabetes found to be a ‘significant risk factor’ among stroke victims

More evidence has been published which supports that diabetes is a “significant…

Public Health England considers low carb approach for type 2 diabetes

The low carb approach is being considered by the government to be…